Fingolimod Teva 0,25 mg tvrde kapsule
| Name | Fingolimod Teva 0,25 mg tvrde kapsule |
|---|---|
| Marketing Authorisation Number | HR-H-438748545 |
| Active Substance | fingolimodklorid |
| Composition | svaka kapsula sadrži 0,25 mg fingolimoda (u obliku fingolimodklorida) |
| Pharmaceutical Form | kapsula, tvrda |
| Manufacturer | Teva Operations Poland Sp. z o.o., Krakow, Poljska
Teva Nederland B.V., Haarlem, Nizozemska Balkanpharma - Dupnitsa AD, Dupnitsa, Bugarska Merckle GmbH, Blaubeuren, Njemačka |
| Marketing Authorisation Holder | Teva GmbH, Graf-Arco-Strasse 3, Ulm, Njemačka |
| Marketing Authorisation Date | 21.09.2020 |
| MA Period of Validity | 21.09.2025 |
| MA Revocation Date | 16.10.2024* |
| Classification Number | UP/I-530-09/19-01/128 |
| Registration Number | 381-12-01/30-20-05 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | ograničeni recept |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | L04AA27 |
| Marketing status | nije stavljeno u promet |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
| Summary of risk management plan | download |
| Educational materials for healthcare professionals |
Lista provjere za zdravstvene radnike, verzija 5 |
| Educational materials for patients / caregivers |
Vodič za bolesnike, verzija 5 Vodič za roditelje skrbnike, verzija 3 Kartica za bolesnice s podsjetnikom o trudnoći, verzija 1 |
*Note
Marketing authorisation has been revoked by request of the marketing authorisation holder. In accordance with Article 113 of Medicinal Products Act (Official Gazette No. 76/13), only a medicinal product in respect of which a marketing authorisation has been granted by the Agency for Medicinal Products and Medical Devices or the European Commision, and a medicinal product in respect of which an authorisation for parallel import or parallel distribution has been granted may be placed on the market of the Republic of Croatia. By way of derogation from this provision, a batch of medicinal product may be on the market for no longer than 18 months following the expiry of revocation of the marketing authorisation, unless its shelf life expires first.
